A retrospective study of transgender people using gender-affirming hormone therapy (GAHT) found excessive undiagnosed hypertension and hyperlipidaemia, suggesting that these individuals should be monitored for heart disease risk .
Dr Kara Denby (Cleveland Clinic, USA) presented the study aiming to identify the baseline cardiovascular risk of transgender individuals presenting for gender-affirming care from a multidisciplinary transgender programme. Transgender people were included if they had not yet initiated GAHT. Collected data included demographics, medical history, vitals, medications, and laboratory results. The ACC/AHA ASCVD and QRISK3 CV risk scores were calculated for all participants without documented CV disease.
Included were 427 participants. Their mean age was 26 years, mean BMI was 29.3 kg/m2. Sex assigned at birth was 238 (55.6%) male, 186 (43.5%) female, and 4 (0.9%) intersex. Gender was 172 (40.2%) men, 236 (55.1%) wo...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Rilonacept reduces risk of pericarditis recurrence Next Article
Children exposed to tobacco smoke have worse heart function as adults »